Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
Research output: Contribution to journal › Journal article › Research › peer-review
To examine the effects of 12 weeks of treatment with the DPP-4 inhibitor, sitagliptin, on gastrointestinal hormone responses to a standardized mixed meal and beta cell secretory capacity, measured as glucose and non-glucose induced insulin secretion during a hyperglycaemic clamp, in patients with type 2 diabetes.
| Original language | English |
|---|---|
| Journal | Diabetes, Obesity and Metabolism |
| Volume | 12 |
| Issue number | 4 |
| Pages (from-to) | 323-33 |
| Number of pages | 11 |
| ISSN | 1462-8902 |
| DOIs | |
| Publication status | Published - 1 Apr 2010 |
- Adult, Aged, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Double-Blind Method, Drug Administration Schedule, Female, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Glucagon-Like Peptide 2, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Peptide YY, Postprandial Period, Pyrazines, Triazoles
Research areas
ID: 33939951